The current drug therapy for PAH, including bosentan, sildenafil, macitentan, riociguat, prostacyclin, and its derivatives, aims to target pathways related to endothelin‐1 (ET‐1), nitric oxide, and vasoconstrictor prostaglandins (Galie et al, 2016a,b). The gene discussed is EDN1; the disease is pulmonary arterial hypertension.